Tim Koldenhof
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tim Koldenhof has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Michiel Rienstra
Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
7 shared publications - Isabelle C. Van Gelder
Department of Cardiology, University of Groningen, University Medical Centre Groningen , Groningen
4 shared publications - Robert G. Tieleman
Department of Cardiology, Martini Hospital, Groningen, the Netherlands
4 shared publications - Harry J. G. M. Crijns
Department of Cardiology and CARIM, Maastricht University, Cardiovascular Research Institute Maastricht, The Netherlands (H.J.G.M.C.).
3 shared publications - Martijn E. van de Lande
Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands
3 shared publications Robert G Tieleman
Department of Cardiology, Martini Hospital, Groningen, Netherlands
3 shared publications
Latest Publications
- Open Access
- 5 March 2026
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 6 (2)
Rate control treatment with calcium channel blockers and beta blockers for patients with atrial fibrillation: a systematic review and meta-analysis
Aims: Controlling heart rate is a key objective in atrial fibrillation (AF) management, commonly achieved with beta blockers or non-dihydropyridine calcium channel blockers, both class I guideline recommendations. However, their long-term effectiveness has rarely been compared. This review aimed to critically evaluate all available evidence comparing these drug classes in AF treatment. Methods and results: We systematically searched MEDLINE, Embase, Web of Science, and Cochrane Central for original studies published up to 1 March 2025. Eligible studies included AF patients, compared calcium channel blockers and beta blockers, and reported heart rate or other clinically relevant outcomes. The primary outcome was 24-hour heart rate on Holter monitoring. Meta-analyses were performed where data were sufficiently homogeneous. Of 1906 identified records, 25 met inclusion criteria. Five studies reported 24-h mean heart rate, showing no difference between drug classes (mean difference: 3.6 b.p.m., 95% CI: −2.9 to 10.1, P = 0.274). Eight studies reported maximum exercise heart rate, which was significantly higher with calcium channel blockers than with beta blockers (mean difference: 10.5 b.p.m., 95% CI: 3.3 to 17.7, P = 0.043). Other outcomes were too heterogeneous for meta-analysis, though three studies reported increased peak oxygen uptake with calcium channel blockers. Conclusion: Calcium channel blockers and beta blockers provide comparable control of mean heart rate in AF. However, patients on calcium channel blockers have a higher maximum heart rate during exercise. In our qualitative synthesis, some studies reported higher peak oxygen uptake calcium channel blocker treated patients, these results should be seen as hypothesis generating.
- 5 March 2026
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 6 (2)
Open AccessRate control treatment with calcium channel blockers and beta blockers for patients with atrial fibrillation: a systematic review and meta-analysis
Aims: Controlling heart rate is a key objective in atrial fibrillation (AF) management, commonly achieved with beta blockers or non-dihydropyridine calcium channel blockers, both class I guideline recommendations. However, their long-term effectiveness has rarely been compared. This review aimed to critically evaluate all available evidence comparing these drug classes in AF treatment. Methods and results: We systematically searched MEDLINE, Embase, Web of Science, and Cochrane Central for original studies published up to 1 March 2025. Eligible studies included AF patients, compared calcium channel blockers and beta blockers, and reported heart rate or other clinically relevant outcomes. The primary outcome was 24-hour heart rate on Holter monitoring. Meta-analyses were performed where data were sufficiently homogeneous. Of 1906 identified records, 25 met inclusion criteria. Five studies reported 24-h mean heart rate, showing no difference between drug classes (mean difference: 3.6 b.p.m., 95% CI: −2.9 to 10.1, P = 0.274). Eight studies reported maximum exercise heart rate, which was significantly higher with calcium channel blockers than with beta blockers (mean difference: 10.5 b.p.m., 95% CI: 3.3 to 17.7, P = 0.043). Other outcomes were too heterogeneous for meta-analysis, though three studies reported increased peak oxygen uptake with calcium channel blockers. Conclusion: Calcium channel blockers and beta blockers provide comparable control of mean heart rate in AF. However, patients on calcium channel blockers have a higher maximum heart rate during exercise. In our qualitative synthesis, some studies reported higher peak oxygen uptake calcium channel blocker treated patients, these results should be seen as hypothesis generating.
Heart rate in early rhythm control therapy in patients with atrial fibrillation
Background Preventing high heart rates in atrial fibrillation (AF) is recommended to reduce AF-related symptoms and morbidity. Evidence on a strong relationship between lower heart rate during AF and a reduction in symptoms or cardiovascular complications is, however, lacking. Methods This Early Treatment of Atrial Fibrillation for Stroke Prevention Trial analysis compared symptoms, treatment strategy and the composite of death from cardiovascular causes, stroke or hospitalisation with worsening of heart failure or acute coronary syndrome between patients with a heart rate Results At baseline, 772 patients were in AF and had information on heart rate available. Mean age was 70.8±7.8 years, 305 (40%) were women, 385 (50%) were randomised to early rhythm control and 506 (66%) patients had a heart rate Conclusion A high heart rate (≥110 beats per minute) during AF is associated with more and more severe AF-related symptoms. Cardiovascular event rates are not different between heart rates. Early rhythm control reduces outcomes in patients with high and low heart rates during AF. Trial registration number NCT01288352.
Heart rate in early rhythm control therapy in patients with atrial fibrillation
Background Preventing high heart rates in atrial fibrillation (AF) is recommended to reduce AF-related symptoms and morbidity. Evidence on a strong relationship between lower heart rate during AF and a reduction in symptoms or cardiovascular complications is, however, lacking. Methods This Early Treatment of Atrial Fibrillation for Stroke Prevention Trial analysis compared symptoms, treatment strategy and the composite of death from cardiovascular causes, stroke or hospitalisation with worsening of heart failure or acute coronary syndrome between patients with a heart rate Results At baseline, 772 patients were in AF and had information on heart rate available. Mean age was 70.8±7.8 years, 305 (40%) were women, 385 (50%) were randomised to early rhythm control and 506 (66%) patients had a heart rate Conclusion A high heart rate (≥110 beats per minute) during AF is associated with more and more severe AF-related symptoms. Cardiovascular event rates are not different between heart rates. Early rhythm control reduces outcomes in patients with high and low heart rates during AF. Trial registration number NCT01288352.
High heart rates during paroxysmal atrial fibrillation: continuous rhythm monitoring data of the RACE V study
Background: Preventing high heart rates in patients with atrial fibrillation (AF) is a key objective of AF management. Data regarding heart rates in patients with paroxysmal AF (PAF) is lacking. This analysis aimed to provide insight into heart rates during PAF episodes measured with continuous implantable loop monitoring. Methods: In present analysis of the Interaction between hyperCoagulability, Electrical remodeling, and Vascular Destabilization in the Progression of AF study, we included 349 patients with at least one year of continuous rhythm monitoring and an episode of AF. Mean heart rates and duration of AF episodes were used to calculate total AF duration and AF duration above different heart rate cut-offs. Results: The median age was 64.0 (58.4 to 70.5) years, 152 (44%) were women and CHA2DS2-VASc score ≥2 or higher in 255 (73%) patients. During 28.3 (21.3 to 35.0) months of follow-up, the median number of AF episodes was 62 (12 to 293) with a median total AF duration of 4.6 (0.8 to 26.8) days. At baseline, 172 (49%) patients used beta-blockers, 64 (18%) used diltiazem or verapamil and 5 (1%) used digoxin. A total of 133 patients (38%) experienced a heart rate >110 bpm for more than 50% of the time during AF. Fifty-six (16%) patients had a heart rate >130 bpm for more than 50% of the time while in AF. During follow-up, 39 patients (11%) received an increase of rate-controlling medication. Conclusion: Continuous rhythm monitoring revealed that more than a third of PAF patients had heart rates above 110 bpm for more than half of their time in AF. Trial registration number: Clinicaltrials.gov identifier NCT02726698.
High heart rates during paroxysmal atrial fibrillation: continuous rhythm monitoring data of the RACE V study
Background: Preventing high heart rates in patients with atrial fibrillation (AF) is a key objective of AF management. Data regarding heart rates in patients with paroxysmal AF (PAF) is lacking. This analysis aimed to provide insight into heart rates during PAF episodes measured with continuous implantable loop monitoring. Methods: In present analysis of the Interaction between hyperCoagulability, Electrical remodeling, and Vascular Destabilization in the Progression of AF study, we included 349 patients with at least one year of continuous rhythm monitoring and an episode of AF. Mean heart rates and duration of AF episodes were used to calculate total AF duration and AF duration above different heart rate cut-offs. Results: The median age was 64.0 (58.4 to 70.5) years, 152 (44%) were women and CHA2DS2-VASc score ≥2 or higher in 255 (73%) patients. During 28.3 (21.3 to 35.0) months of follow-up, the median number of AF episodes was 62 (12 to 293) with a median total AF duration of 4.6 (0.8 to 26.8) days. At baseline, 172 (49%) patients used beta-blockers, 64 (18%) used diltiazem or verapamil and 5 (1%) used digoxin. A total of 133 patients (38%) experienced a heart rate >110 bpm for more than 50% of the time during AF. Fifty-six (16%) patients had a heart rate >130 bpm for more than 50% of the time while in AF. During follow-up, 39 patients (11%) received an increase of rate-controlling medication. Conclusion: Continuous rhythm monitoring revealed that more than a third of PAF patients had heart rates above 110 bpm for more than half of their time in AF. Trial registration number: Clinicaltrials.gov identifier NCT02726698.
Rate control in atrial fibrillation, calcium channel blockers versus beta-blockers
Objective To investigate heart rate differences between non-dihydropyridine calcium channel blockers and beta-blockers in patients with non-permanent atrial fibrillation (AF). Methods Using data from ‘A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation’ (AFFIRM), where patients were randomised 1:1 rate or rhythm control, we compared the effect of rate control drugs on heart rate during AF as well as during sinus rhythm. Multivariable logistic regression was used to adjust for baseline characteristics. Results A total of 4060 patients were enrolled in the AFFIRM trial, mean age was 70±9 years, 39% were women. Out of the total, 1112 patients were in sinus rhythm at baseline and used either non-dihydropyridine channel blockers or beta-blockers. Of them, 474 had AF during follow-up while remaining on the same rate control drugs, 218 (46%) on calcium channel blockers and 256 (54%) on beta-blockers. Mean age of calcium channel blocker patients was 70±8 years and 68±8 for beta-blocker patients (p=0.003), 42% were women. A resting heart rate Conclusion In patients with non-permanent AF, calcium channel blockers instituted for rate control were associated with less bradycardia during sinus rhythm compared with beta-blockers.
Rate control in atrial fibrillation, calcium channel blockers versus beta-blockers
Objective To investigate heart rate differences between non-dihydropyridine calcium channel blockers and beta-blockers in patients with non-permanent atrial fibrillation (AF). Methods Using data from ‘A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation’ (AFFIRM), where patients were randomised 1:1 rate or rhythm control, we compared the effect of rate control drugs on heart rate during AF as well as during sinus rhythm. Multivariable logistic regression was used to adjust for baseline characteristics. Results A total of 4060 patients were enrolled in the AFFIRM trial, mean age was 70±9 years, 39% were women. Out of the total, 1112 patients were in sinus rhythm at baseline and used either non-dihydropyridine channel blockers or beta-blockers. Of them, 474 had AF during follow-up while remaining on the same rate control drugs, 218 (46%) on calcium channel blockers and 256 (54%) on beta-blockers. Mean age of calcium channel blocker patients was 70±8 years and 68±8 for beta-blocker patients (p=0.003), 42% were women. A resting heart rate Conclusion In patients with non-permanent AF, calcium channel blockers instituted for rate control were associated with less bradycardia during sinus rhythm compared with beta-blockers.
- Open Access
- 27 March 2023
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 25 (5)
Time of onset of atrial fibrillation and atrial fibrillation progression data from the RACE V study
Atrial fibrillation (AF) progression is associated with adverse outcome, but the role of the circadian or diurnal pattern of AF onset remains unclear. We aim to assess the association between the time of onset of AF episodes with the clinical phenotype and AF progression in patients with self-terminating AF. The Reappraisal of AF: Interaction Between Hypercoagulability, Electrical Remodelling, and Vascular Destabilization in the Progression of AF study included patients with self-terminating AF who underwent extensive phenotyping at baseline and continuous rhythm monitoring with an implantable loop recorder (ILR). In this subanalysis, ILR data were used to assess the development of AF progression and the diurnal pattern of AF onset: predominant (>80%) nocturnal AF, predominant daytime AF, or mixed AF without a predominant diurnal AF pattern. The median follow-up was 2.2 (1.6–2.8) years. The median age was 66 (59–71) years, and 117 (42%) were women. Predominant nocturnal (n = 40) and daytime (n = 43) AF onset patients had less comorbidities compared to that of mixed (n = 195) AF patients (median 2 vs. 2 vs. 3, respectively, P = 0.012). Diabetes was more common in the mixed group (12% vs. 5% vs. 0%, respectively, P = 0.031), whilst obesity was more frequent in the nocturnal group (38% vs. 12% vs. 27%, respectively, P = 0.028). Progression rates in the nocturnal vs. daytime vs. mixed groups were 5% vs. 5% vs. 24%, respectively (P = 0.013 nocturnal vs. mixed and P = 0.008 daytime vs. mixed group, respectively). In self-terminating AF, patients with either predominant nocturnal or daytime onset of AF episodes had less associated comorbidities and less AF progression compared to that of patients with mixed onset of AF. NCT02726698
- 27 March 2023
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 25 (5)
Open AccessTime of onset of atrial fibrillation and atrial fibrillation progression data from the RACE V study
Atrial fibrillation (AF) progression is associated with adverse outcome, but the role of the circadian or diurnal pattern of AF onset remains unclear. We aim to assess the association between the time of onset of AF episodes with the clinical phenotype and AF progression in patients with self-terminating AF. The Reappraisal of AF: Interaction Between Hypercoagulability, Electrical Remodelling, and Vascular Destabilization in the Progression of AF study included patients with self-terminating AF who underwent extensive phenotyping at baseline and continuous rhythm monitoring with an implantable loop recorder (ILR). In this subanalysis, ILR data were used to assess the development of AF progression and the diurnal pattern of AF onset: predominant (>80%) nocturnal AF, predominant daytime AF, or mixed AF without a predominant diurnal AF pattern. The median follow-up was 2.2 (1.6–2.8) years. The median age was 66 (59–71) years, and 117 (42%) were women. Predominant nocturnal (n = 40) and daytime (n = 43) AF onset patients had less comorbidities compared to that of mixed (n = 195) AF patients (median 2 vs. 2 vs. 3, respectively, P = 0.012). Diabetes was more common in the mixed group (12% vs. 5% vs. 0%, respectively, P = 0.031), whilst obesity was more frequent in the nocturnal group (38% vs. 12% vs. 27%, respectively, P = 0.028). Progression rates in the nocturnal vs. daytime vs. mixed groups were 5% vs. 5% vs. 24%, respectively (P = 0.013 nocturnal vs. mixed and P = 0.008 daytime vs. mixed group, respectively). In self-terminating AF, patients with either predominant nocturnal or daytime onset of AF episodes had less associated comorbidities and less AF progression compared to that of patients with mixed onset of AF. NCT02726698
- Open Access
- 1 March 2023
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 25 (4) , 1323-1331
Clinical utility of the 4S-AF scheme in predicting progression of atrial fibrillation: data from the RACE V study
The recent 4S-AF (scheme proposed by the 2020 ESC AF guidelines to address stroke risk, symptom severity, severity of AF burden and substrate of AF to provide a structured phenotyping of AF patients in clinical practice to guide therapy and assess prognosis) scheme has been proposed as a structured scheme to characterize patients with atrial fibrillation (AF). We aimed to assess whether the 4S-AF scheme predicts AF progression in patients with self-terminating AF. We analysed 341 patients with self-terminating AF included in the well-phenotyped Reappraisal of Atrial Fibrillation: Interaction between HyperCoagulability, Electrical remodelling, and Vascular Destabilization in the Progression of AF (RACE V) study. Patients had continuous monitoring with implantable loop recorders or pacemakers. AF progression was defined as progression to persistent or permanent AF or progression of self-terminating AF with >3% burden increase. Progression of AF was observed in 42 patients (12.3%, 5.9% per year). Patients were given a score based on the components of the 4S-AF scheme. Mean age was 65 [interquartile range (IQR) 58–71] years, 149 (44%) were women, 103 (49%) had heart failure, 276 (81%) had hypertension, and 38 (11%) had coronary artery disease. Median CHA2DS2-VASc (the CHA2DS2–VASc score assesses thromboembolic risk. C, congestive heart failure/left ventricular dysfunction; H, hypertension; A2, age ≥ 75 years; D, diabetes mellitus; S2, stroke/transient ischaemic attack/systemic embolism; V, vascular disease; A, age 65–74 years; Sc, sex category (female sex)) score was 2 (IQR 2–3), and median follow-up was 2.1 (1.5–2.6) years. The average score of the 4S-AF scheme was 4.6 ± 1.4. The score points from the 4S-AF scheme did not predict the risk of AF progression [odds ratio (OR) 1.1 95% CI 0.88–1.41, C-statistic 0.53]. However, excluding the symptoms domain, resulting in the 3S-AF (4S-AF scheme without the domain symptom severity, only including stroke risk, severity of AF burden and substrate of AF) scheme, predicted the risk of progression (OR 1.59 95% CI 1.15–2.27, C-statistic 0.62) even after adjusting for sex and age. In self-terminating AF patients, the 4S-AF scheme does not predict AF progression. The 3S-AF scheme, excluding the symptom domain, may be a more appropriate score to predict AF progression. Clinicaltrials.gov NCT02726698 for RACE V
- 1 March 2023
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 25 (4) , 1323-1331
Open AccessClinical utility of the 4S-AF scheme in predicting progression of atrial fibrillation: data from the RACE V study
The recent 4S-AF (scheme proposed by the 2020 ESC AF guidelines to address stroke risk, symptom severity, severity of AF burden and substrate of AF to provide a structured phenotyping of AF patients in clinical practice to guide therapy and assess prognosis) scheme has been proposed as a structured scheme to characterize patients with atrial fibrillation (AF). We aimed to assess whether the 4S-AF scheme predicts AF progression in patients with self-terminating AF. We analysed 341 patients with self-terminating AF included in the well-phenotyped Reappraisal of Atrial Fibrillation: Interaction between HyperCoagulability, Electrical remodelling, and Vascular Destabilization in the Progression of AF (RACE V) study. Patients had continuous monitoring with implantable loop recorders or pacemakers. AF progression was defined as progression to persistent or permanent AF or progression of self-terminating AF with >3% burden increase. Progression of AF was observed in 42 patients (12.3%, 5.9% per year). Patients were given a score based on the components of the 4S-AF scheme. Mean age was 65 [interquartile range (IQR) 58–71] years, 149 (44%) were women, 103 (49%) had heart failure, 276 (81%) had hypertension, and 38 (11%) had coronary artery disease. Median CHA2DS2-VASc (the CHA2DS2–VASc score assesses thromboembolic risk. C, congestive heart failure/left ventricular dysfunction; H, hypertension; A2, age ≥ 75 years; D, diabetes mellitus; S2, stroke/transient ischaemic attack/systemic embolism; V, vascular disease; A, age 65–74 years; Sc, sex category (female sex)) score was 2 (IQR 2–3), and median follow-up was 2.1 (1.5–2.6) years. The average score of the 4S-AF scheme was 4.6 ± 1.4. The score points from the 4S-AF scheme did not predict the risk of AF progression [odds ratio (OR) 1.1 95% CI 0.88–1.41, C-statistic 0.53]. However, excluding the symptoms domain, resulting in the 3S-AF (4S-AF scheme without the domain symptom severity, only including stroke risk, severity of AF burden and substrate of AF) scheme, predicted the risk of progression (OR 1.59 95% CI 1.15–2.27, C-statistic 0.62) even after adjusting for sex and age. In self-terminating AF patients, the 4S-AF scheme does not predict AF progression. The 3S-AF scheme, excluding the symptom domain, may be a more appropriate score to predict AF progression. Clinicaltrials.gov NCT02726698 for RACE V
- Open Access
- 20 August 2021
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 24 (3) , 384-389
Rate control drugs differ in the prevention of progression of atrial fibrillation
We hypothesize that in patients with paroxysmal atrial fibrillation (AF), verapamil is associated with lower AF progression compared to beta blockers or no rate control. In this pre-specified post hoc analysis of the RACE 4 randomized trial, the effect of rate control medication on AF progression in paroxysmal AF was analysed. Patients using Vaughan-Williams Class I or III antiarrhythmic drugs were excluded. The primary outcome was a composite of first electrical cardioversion (ECV), chemical cardioversion (CCV), or atrial ablation. Event rates are displayed using Kaplan–Meier curves and multivariable Cox regression analyses are used to adjust for baseline differences. Out of 666 patients with paroxysmal AF, 47 used verapamil, 383 used beta blockers, and 236 did not use rate control drugs. The verapamil group was significantly younger than the beta blocker group and contained more men than the no rate control group. Over a mean follow-up of 37 months, the primary outcome occurred in 17% in the verapamil group, 33% in the beta blocker group, and 33% in the no rate control group (P = 0.038). After adjusting for baseline characteristics, patients using verapamil have a significantly lower chance of receiving ECV, CCV, or atrial ablation compared to patients using beta blockers [hazard ratio (HR) 0.40, 95% confidence interval (CI) 0.19–0.83] and no rate control (HR 0.64, 95% CI 0.44–0.93). In patients with newly diagnosed paroxysmal AF, verapamil was associated with less AF progression, as compared to beta blockers and no rate control.
- 20 August 2021
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 24 (3) , 384-389
Open AccessRate control drugs differ in the prevention of progression of atrial fibrillation
We hypothesize that in patients with paroxysmal atrial fibrillation (AF), verapamil is associated with lower AF progression compared to beta blockers or no rate control. In this pre-specified post hoc analysis of the RACE 4 randomized trial, the effect of rate control medication on AF progression in paroxysmal AF was analysed. Patients using Vaughan-Williams Class I or III antiarrhythmic drugs were excluded. The primary outcome was a composite of first electrical cardioversion (ECV), chemical cardioversion (CCV), or atrial ablation. Event rates are displayed using Kaplan–Meier curves and multivariable Cox regression analyses are used to adjust for baseline differences. Out of 666 patients with paroxysmal AF, 47 used verapamil, 383 used beta blockers, and 236 did not use rate control drugs. The verapamil group was significantly younger than the beta blocker group and contained more men than the no rate control group. Over a mean follow-up of 37 months, the primary outcome occurred in 17% in the verapamil group, 33% in the beta blocker group, and 33% in the no rate control group (P = 0.038). After adjusting for baseline characteristics, patients using verapamil have a significantly lower chance of receiving ECV, CCV, or atrial ablation compared to patients using beta blockers [hazard ratio (HR) 0.40, 95% confidence interval (CI) 0.19–0.83] and no rate control (HR 0.64, 95% CI 0.44–0.93). In patients with newly diagnosed paroxysmal AF, verapamil was associated with less AF progression, as compared to beta blockers and no rate control.